TY - JOUR
T1 - High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma
AU - Rossi, H. A.
AU - Becker, P. S.
AU - Emmons, R. V.B.
AU - Westervelt, P.
AU - Levy, W.
AU - Liu, Q.
AU - Clark, Y.
AU - Ballen, K.
PY - 2003/3
Y1 - 2003/3
N2 - Allogeneic stem cell transplantation (SCT) has been shown to be a curative therapy for some patients with non-Hodgkin's lymphoma (NHL). Total-body irradiation and high-dose cyclophosphamide combinations are the most established conditioning regimens used in this setting. We examined the efficacy and toxicity of cyclophosphamide, BCNU, and VP-16 (CBV) as a suitable chemotherapy-only regimen for NHL patients. In total, 18 patients, median age 42 years, with NHL were treated with CBV followed by allotransplant. Patients had received a median of two prior chemotherapy regimens. Median times to neutrophil and platelet recovery were 19 and 15 days, respectively. Interstitial pneumonitis occurred in one patient. There have been four relapses after a median follow-up of 39 months. Overall, there were four deaths, one because of relapse. The 2-year estimates of relapse-free and overall survival are 56 and 76%, respectively. CBV is a safe and an effective alternative to TBI-containing regimens before allogeneic SCT for NHL.
AB - Allogeneic stem cell transplantation (SCT) has been shown to be a curative therapy for some patients with non-Hodgkin's lymphoma (NHL). Total-body irradiation and high-dose cyclophosphamide combinations are the most established conditioning regimens used in this setting. We examined the efficacy and toxicity of cyclophosphamide, BCNU, and VP-16 (CBV) as a suitable chemotherapy-only regimen for NHL patients. In total, 18 patients, median age 42 years, with NHL were treated with CBV followed by allotransplant. Patients had received a median of two prior chemotherapy regimens. Median times to neutrophil and platelet recovery were 19 and 15 days, respectively. Interstitial pneumonitis occurred in one patient. There have been four relapses after a median follow-up of 39 months. Overall, there were four deaths, one because of relapse. The 2-year estimates of relapse-free and overall survival are 56 and 76%, respectively. CBV is a safe and an effective alternative to TBI-containing regimens before allogeneic SCT for NHL.
KW - Allogeneic
KW - Carmustine
KW - Conditioning therapy
KW - Non-Hodgkin lymphoma
KW - Stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=0242500987&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1703874
DO - 10.1038/sj.bmt.1703874
M3 - Review article
C2 - 12665838
AN - SCOPUS:0242500987
SN - 0268-3369
VL - 31
SP - 441
EP - 446
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 6
ER -